论文部分内容阅读
目的:观察国产头孢吡肟治疗慢性阻塞性肺疾病急性加重期(AECOPD)并呼吸衰竭的疗效及安全性。方法:96例AE-COPD并呼吸衰竭患者随机分成A组(n=48)与B组(n=48),分别给予头孢吡肟、头孢哌酮钠/他唑巴坦钠治疗。2组给药剂量均为2.0g,静脉滴注,bid,疗程7～14d。结果:A组与B组总有效率分别为82%、62%(P<0.01);A组与B组痰菌清除率分别为79.1%、45.8%(P<0.05);A组与B组不良反应发生率分别为8.3%、10.4%(P>0.05)。结论:头孢吡肟治疗AECOPD并呼吸衰竭疗效优于头孢哌酮钠/他唑巴坦钠,两者均有较好的安全性。
Objective: To observe the efficacy and safety of domestic cefepime in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and respiratory failure. Methods: A total of 96 patients with AE-COPD and respiratory failure were randomly divided into group A (n = 48) and group B (n = 48). Cefepime and cefoperazone sodium / tazobactam sodium were given respectively. The dosage of 2 groups were 2.0g, intravenous drip, bid, treatment 7 ~ 14d. Results: The total effective rates of group A and group B were 82% and 62%, respectively (P <0.01). The sputum bacterial clearance rates of group A and group B were 79.1% and 45.8%, respectively (P <0.05) Adverse reactions were 8.3%, 10.4% (P> 0.05). Conclusion: The efficacy of cefepime in the treatment of AECOPD with respiratory failure is better than that of cefoperazone sodium / tazobactam sodium, both of which have good safety.